Project: Rapid Diagnostics of Tick-borne diseases
The project summary and CO outputs of the project are as follows:_x000D__x000D_1. Developing flavivirus Enzyme ImmunoAssay (EIA) and rapid diagnostic devices for manufacture and commercialisation_x000D_2. Developing a simultaneous instrumental lateral flow (LF) rapid assay for serodiagnostics of Tick-borne TBE and Lyme borreliosis giving assay result in a couple of minutes_x000D_3. Cloning, optimising expression, production and purification of TBE preME, NS1, borrelia and other viable antigens for the test development for the use in (1) and (2) above_x000D_4. Optimising antigens for typing the different tick-borne diseases and differentation of vaccination versus infection immunity of TBE for the use in (1) and (2) above_x000D_5. Antibody development (such Anti-NS1) as for the use in (1)-(4) above_x000D__x000D_Upto now there is no commercially available rapid diagnostic devices for Lyme disease or TBE._x000D__x000D__x000D_The project consortium consists of:_x000D__x000D_1. Reagena Oy Ltd (CO participant) _x000D_and leading flavivirus research institutes in two Nordic countries_x000D_2. Karoliniska Institutet, Department of Microbiology, Tumor and Cell Biology (professor Åke Lundkvist)_x000D_3. University of Helsinki, Department of Virology, Haartman Institute (professors Olli Vapalahti and Antti Vaheri)_x000D__x000D_
| Acronym | RDT REAG (Reference Number: 5939) |
| Duration | 10/02/2011 - 31/12/2013 |
| Project Topic | Novel and innovative commercial rapid serodiagnostic devices are developed for tick-borne infectious disease diagnostics. Currently there are no rapid assays available for the major tick-borne viral TBE and bacterial Lyme borreliosis infections. A simultaneous instrumental rapid device is targeted. |
|
Project Results (after finalisation) |
1. Developing flavivirus Enzyme ImmunoAssay (EIA) and rapid diagnostic devices for manufacture and commercialization _x000D_2. Developing an unique instrumental lateral flow (LF) rapid assay for serodiagnostics of Tick-borne TBE (Tick-borne Encephalitis) giving assay result in a couple of minutes _x000D_3. Cloning, optimising expression, production and purification of TBE preME, NS1, borrelia and other viable antigens for the test development for the use in (1) and (2) above _x000D_4. Optimising antigens for typing the different tick-borne diseases and differentation of vaccination versus infection immunity of TBE for the use in (1) and (2) above _x000D_ |
| Network | Eurostars |
| Call | Eurostars Cut-Off 5 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 4 | Karoliniska Institutet, Department of Microbiology, Tumor and Cell Biology | Partner | Sweden |
| 4 | Oy Reagena Ltd | Coordinator | Finland |
| 4 | Oy Reagena Ltd | Coordinator | Finland |
| 4 | University of Helsinki, Virology Department, Haartman Institute | Partner | Finland |